Therapeutic potential of snake venom, l-amino oxidase and sorafenib in hepatocellular carcinoma

Mahfouz, Dalia H.; El-Magd, Mohammed A.; Mansour, Ghada H.; Wahab, Abdel; Abdelhamid, Ismail A.; El-Zayat, Emad

doi:10.1007/s13273-021-00151-8

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer therapy involves surgery, chemotherapy, radiation, hormonal, and biological approaches. Struggles have been made to recognize natural and synthetic anticancer with antioxidant properties 5 – 7 . Alternatively, both anticancer and herbal extract with antioxidant properties could be given together during cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage

Attia

Salama

Eldiasty

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The burden of cancer diseases is increasing every year, therefore, the demands to figure out novel drugs that can retain antitumor properties have been raised. This study aimed to investigate the anti-tumor properties of amygdalin (Amy) against Ehrlich ascites carcinoma (EAC) bearing mice and its protective properties against liver damage. Amy and the standard anticancer drug Sorafenib (Sor) were given alone or in combination to Swiss albino female mice that had been injected with EAC cells. Biochemical parameters of liver function (AST, ALT, GGT, total protein, albumin), tumor volume, oxidative stress [malondialdehyde, (MDA)] and antioxidative [superoxide dismutase (SOD), and reduced glutathione (GSH)] markers were measured. The hepatic expression of the antioxidant-related gene [nuclear factor erythroid-2-related factor 2 (Nrf2)], the migration-related gene [matrix metalloprotease 9 (MMP9)], and the angiogenesis-related gene [vascular endothelial growth factor (VEGF)] were evaluated by qPCR. The results revealed that EAC-bearing mice treated with Amy and/or Sor showed a decrease in the tumor burden and hepatic damage as evidenced by (1) decreased tumor volume, number of viable tumor cells; (2) increased number of dead tumor cells; (3) restored the liver function parameters; (4) reduced hepatic MDA levels; (5) enhanced hepatic GSH and SOD levels; (6) upregulated expression of Nrf2; (7) downregulated expression of MMP9 and VEGF, and (8) improved hepatic structure. Among all treatments, mice co-treated with Amy (orally) and Sor (intraperitoneally) showed the best effect. With these results, we concluded that the Amy improved the antitumor effect of Sor and had a protective role on liver damage induced by EAC in mice.

show abstract

Section: Introductionmentioning

confidence: 99%

Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage

Attia

Salama

Eldiasty

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Low molecular weight peptides from the Iranian scorpion decrease the viability of 3D culture of HepG2 cells by inducing apoptosis ( 66 ). Snake venom and L-amino acid oxidase inhibit the proliferation of HepG2 cells and act synergistically with sorafenib to induce apoptosis ( 67 ). Batroxin, a peptide from Bothrops atox venom, decreases cell viability of HepG2 in an apoptosis dependent manner ( 68 ).…”

Section: Exploring Venom Peptide Therapies For Targeting Hccmentioning

confidence: 99%

Targeting Dysregulated Ion Channels in Liver Tumors with Venom Peptides

Achimba,

Faezov,

Cohen

et al. 2023

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

The regulation of cellular processes by ion channels has become central to the study of cancer mechanisms. Designing molecules that can modify ion channels specific to tumor cells is a promising area of targeted drug delivery and therapy. Despite their potential in drug discovery, venom peptides – a group of natural products – have largely remained understudied and under-characterized. In general, venom peptides display high specificity and selectivity for target ion channels. Therefore, they may represent an effective strategy for selectively targeting the dysregulation of ion channels in tumor cells. This review examines existing venom peptide therapies for different cancer types and focuses on the application of snail venom peptides in hepatocellular carcinoma (HCC), the most common form of primary liver cancer worldwide. We provide insights into the mode of action of venom peptides that have been shown to target tumors. We also explore the benefit of using new computational methods like de novo protein structure prediction to screen venom peptides and identify potential druggable candidates. Finally, we summarize the role of cell culture, animal, and organoid models in developing effective therapies against HCC and highlight the need for creating models that represent the most disproportionately affected ethnicities in HCC.

show abstract

Camel milk extracellular vesicles/exosomes: a fascinating frontier in isolation and therapeutic potential

Badawy,

El-Hofey,

Shaban

et al. 2025

Food Funct.

View full text Add to dashboard Cite

show abstract

Therapeutic potential of snake venom, l-amino oxidase and sorafenib in hepatocellular carcinoma

Cited by 4 publications

References 33 publications

Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage

Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage

Targeting Dysregulated Ion Channels in Liver Tumors with Venom Peptides

Camel milk extracellular vesicles/exosomes: a fascinating frontier in isolation and therapeutic potential

Contact Info

Product

Resources

About